Fundraising Fox
Palm Therapeutics
5 employees on LinkedIn · 1 known investors
Find your way into Palm Therapeutics
Sign up to see every warm intro you have to Palm Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Palm Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.
Founders & leadership
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $467.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $585.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Palm Therapeutics do?
- Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.
- Who founded Palm Therapeutics?
- Palm Therapeutics was founded by Andrew Rudd.
- Who are Palm Therapeutics's investors?
- Palm Therapeutics's investors include Tachyon Ventures.